# Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer

> **NCT00002913** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (actual)

## Conditions studied

- Brenner Tumor
- Ovarian Clear Cell Cystadenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Mixed Epithelial Carcinoma
- Ovarian Mucinous Cystadenocarcinoma
- Ovarian Serous Cystadenocarcinoma
- Ovarian Undifferentiated Adenocarcinoma
- Stage III Ovarian Epithelial Cancer
- Stage IV Ovarian Epithelial Cancer

## Interventions

- **DRUG:** paclitaxel
- **DRUG:** cisplatin
- **DRUG:** topotecan hydrochloride
- **BIOLOGICAL:** filgrastim

## Key facts

- **NCT ID:** NCT00002913
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-12
- **Primary completion:** 2007-07
- **Final completion:** —
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2013-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002913, "Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00002913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*